L-cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1 cytopathic effects, replication, and infectivity

Yaffa Mizrachi, Meir Lev, Z. Harish, S. K. Sundaram, A. Rubinstein

Research output: Contribution to journalArticle

15 Scopus citations


Drugs that reduce viral production or prevent viral spread by interference with the host's cellular components are unlikely to induce resistance, in contrast to treatment modalities that interact with the HIV-1 life cycle. Two features make L-cycloserine (L-CS) a candidate drug of this kind: (a) L-CS is a potent inhibitor of the sphingolipid pathway (b) sphingolipids, galactocerebrosides, and sulfatides have been shown, by others, to bind gp120. In a feasibility and efficacy study, we have found that L-CS inhibits HIV-1 replication in a CD4+ lymphoid cell line (CEM) as documented by the reduction of syncytium formation, the number of HIV-1 infected cells, and p24 protein production. This observation may lead to a new strategy for the treatment of HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)137-141
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Issue number2
Publication statusPublished - Jan 1 1996



  • HIV-1
  • L-Cycloserine
  • Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this